✦ LIBER ✦

Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52

✍ Scribed by James N. Ingle; Vera J. Suman; James A. Mailliard; John W. Kugler; James E. Krook; John C. Michalak; Thomas M. Pisansky; Lester E. Wold; John H. Donohue; Matthew P. Goetz; Edith A. Perez

Publisher: Springer US
Year: 2006
Tongue: English
Weight: 197 KB
Volume: 98
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-005-9152-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cost-effectiveness analysis of anastrozo

Cost-effectiveness analysis of anastrozole versus tamoxifen as primary adjuvant therapy for postmenopausal women with early breast cancer: a US healthcare system perspective. The 5-year completed treatment analysis of the ATAC (‘Arimidex’, Tamoxifen Alone or in Combination) trial

✍ Gershon Y. Locker; Robert Mansel; David Cella; Deborah Dobrez; Sonja Sorensen; S 📂 Article 📅 2007 🏛 Springer US 🌐 English ⚖ 267 KB